Abstract | BACKGROUND: METHODS: Patients, who had previously undergone a maximum of 2 regimens of chemotherapy, received 3 cycles of induction therapy with paclitaxel (90 mg/m2 intravenously on days 1, 8, and 15 followed by 1-week drug holiday) and bevacizumab (10 mg/kg intravenously after the completion of paclitaxel administration on days 1 and 15). Patients who had complete response, partial response, or stable disease underwent switch maintenance therapy with eribulin (1.4 mg/m2 intravenously on days 1 and 8 followed by 1-week drug holiday). The primary endpoint was time to treatment failure (TTF) for ISMT. RESULTS: Fifty-one eligible patients (median age: 66 years; range: 35-74) were enrolled: 19 (37.3%) and 32 (62.7%) had stage IV and recurrence, respectively, 42 (82.4%) had visceral metastases, and 45 (88.2%) received eribulin-38 of whom showed disease progression, and 40 (78.4%) underwent post therapy. Median TTF was 9.2 months (95% confidence interval [CI]: 7.3-11.1), median progression-free survival was 10.7 months (95% CI: 9.6-11.8), and median overall survival was 20.0 months (95% CI: 16.0-24.0). Relative dose intensity was 97.7% (range: 33.3-100.0) for induction therapy and was 83.3% (range: 49.3-100.6%) for eribulin maintenance therapy. The most common adverse event was alopecia (51 [100%]) in induction therapy and was peripheral sensory neuropathy (37 [82.2%]) in eribulin maintenance therapy. Eribulin was effective with manageable tolerability. CONCLUSIONS: ISMT may be a promising therapeutic option for patients with MBC. TRIAL REGISTRATION: UMIN000015971 . Registration date: January 1, 2015.
|
Authors | Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Kei Kimizuka, Masafumi Kurosumi |
Journal | BMC cancer
(BMC Cancer)
Vol. 18
Issue 1
Pg. 671
(Jun 20 2018)
ISSN: 1471-2407 [Electronic] England |
PMID | 29925345
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Furans
- Ketones
- Bevacizumab
- eribulin
- Paclitaxel
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Asian People
- Bevacizumab
(administration & dosage)
- Breast Neoplasms
(drug therapy, mortality)
- Female
- Furans
(therapeutic use)
- Humans
- Induction Chemotherapy
(methods)
- Kaplan-Meier Estimate
- Ketones
(therapeutic use)
- Maintenance Chemotherapy
(methods)
- Middle Aged
- Paclitaxel
(administration & dosage)
- Treatment Outcome
|